Yeji

$CORT

CORCEPT THERAPEUTICS INC

Runway:5+ yrs
NasdaqMarket cap: —CIK 0001088856

Insider signals· last 90 days

DateInsiderSharesPriceValue
2026-03-17
BAKER G LEONARD JRDirector
24,218$33.56$0.81M
2026-03-17
BAKER G LEONARD JRDirector
75,782$33.00$2.50M

Upcoming catalysts

6 surfaced
PDUFAJul 11, 2026· in 35d
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July 11, 2026 for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.”
NDA/BLA filedDate TBD~ low confidence
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the Company has submitted a new drug application to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer”
NDA/BLA filedDate TBD
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the Company has submitted a new drug application to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome)”
NDA/BLA filedDate TBD~ low confidence
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“Corcept Therapeutics Incorporated (NASDAQ: CORT)... has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant ovarian cancer.”
NDA/BLA filedDate TBD
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the U.S. Food and Drug Administration has accepted the Company's New Drug Application for relacorilant as a treatment for patients with platinum-resistant ovarian cancer”
NDA/BLA filedDate TBD
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome).”

Drug pipeline

relacorilant
hypertension secondary to hypercortisolism
lifyorli
CORT113176 Lipid Capsule Formulation
Healthy Adults
Miricorilant Treatment A
Healthy
CORT125134
Healthy
Mifepristone
Depressive Disorder, Major
Dazucorilant
Healthy Adults
Exicorilant
Metastatic Castration-Resistant Prostate Cancer
Miricorilant 300 mg tablets
Healthy
CORT125236
Healthy
Relacorilant under fasted conditions
Healthy
Miricorilant
Nonalcoholic Steatohepatitis (NASH)
CORT118335 Oral
Healthy
Miricorilant 150 mg
Nonalcoholic Steatohepatitis (NASH)
CORT118335, 25 mg
Healthy
Miricorlilant
Antipsychotic-induced Weight Gain (AIWG)
CORT125281, 40mg, fasted
Healthy
Relacorilant 150 mg once daily (QD)
Ovarian Cancer
Relacorilant with nab-paclitaxel
Solid Tumors
Nenocorilant 200 mg
Neoplasms
Relacorilant Fasted
Healthy
14C-CORT125281
Healthy
No intervention
Cushing's Syndrome
CORT125134 150 mg
Healthy
Cushing's syndrome confirmation
Cushing's Syndrome
CORT113176
Healthy Adults
Mifepristone 300 MG
Drug Interaction Potentiation
Mifepristone 300 MG [Korlym]
Hypercortisolism
Nab-paclitaxel 80 mg/m^2
Ovarian Neoplasm
Risperidone
Healthy
mifepristone + fluvastatin
Healthy Subjects
Relacorilant 350mg
Healthy
MRI-PDFF
Nonalcoholic Steatohepatitis (NASH)
[14C]-CORT125134
Healthy
CORT125329 lipid capsule formulation
Healthy
Relacorilant, 100 mg and 25 mg
Metastatic Pancreatic Ductal Adenocarcinoma
Dazucorilant 300 mg
Amyotrophic Lateral Sclerosis
Mifepristone and Eribulin in combination
Breast Cancer
[14C]-CORT113176
Healthy
Midazolam hydrochloride
Healthy
Olanzapine
Antipsychotic-induced Weight Gain
Dabigatran Etexilate
Cushing Syndrome

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT07259317Relacorilant 150 mg once daily (QD)Phase 2Recruiting2027-07-01
NCT03604198relacorilantPhase 2Active Not Recruiting2026-12-01
NCT07553663MiricorilantPhase 1Recruiting2026-10-30
NCT06108219MiricorilantPhase 2Active Not Recruiting2026-09-01
NCT07276373Nenocorilant 200 mgPhase 2Recruiting2026-09-01
NCT05407324Dazucorilant 300 mgPhase 2Recruiting2026-09-01
NCT06906341Relacorilant 150 mg once daily (QD)Phase 2Recruiting2026-08-01
NCT06947304MiricorilantPhase 1Recruiting2026-05-01
NCT07240116Miricorilant Treatment APhase 1Completed2026-03-03
NCT06829537——Completed2025-12-08
NCT05257408Nab-paclitaxel 80 mg/m^2Phase 3Active Not Recruiting2025-03-24
NCT06928779DazucorilantPhase 1Completed2024-12-09
NCT05772169Mifepristone 300 MG [Korlym]Phase 4Completed2024-11-19
NCT04308590relacorilantPhase 3Completed2024-09-19
NCT05553470MiricorilantPhase 1Completed2024-09-13
NCT06495944DazucorilantPhase 1Completed2024-08-02
NCT03697109relacorilantPhase 3Completed2024-04-08
NCT05117489Miricorilant 150 mgPhase 1Completed2024-01-29
NCT04373265relacorilantPhase 1Completed2023-10-17
NCT05320146MRI-PDFF—Completed2023-07-18

Recent catalysts

FDA approvalMar 25, 2026· 73d ago· success
$CORTCORCEPT THERAPEUTICS INC
lifyorli
“openFDA ORIG (TYPE 1) approval of LIFYORLI — application NDA220641”
CRLDec 31, 2025· 157d ago
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism”
PDUFADec 30, 2025· 158d ago
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of December 30, 2025 for relacorilant as a treatment for patients with hypercortisolism.”
NDA/BLA filedSep 10, 2025· 269d ago
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the U.S. Food and Drug Administration (FDA) has accepted Corcept's New Drug Application (NDA) for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.”
NDA/BLA filedMar 3, 2025· 460d ago· unknown
$CORTCORCEPT THERAPEUTICS INC
relacorilant · hypertension secondary to hypercortisolism
“the U.S. Food and Drug Administration filed the Company's New Drug Application submission for its proprietary, selective cortisol modulator, relacorilant, to treat patients with endogenous hypercortisolism (Cushing's syndrome)”